CTOs on the Move

Visterra Incorporated

www.visterrainc.com

 
Visterra is a biotechnology company that uses its proprietary Hierotope™ Platform to identify unique disease targets and design and engineer effective therapeutics. The company`s technology is powered by computational tools and techniques, the core of which is Atomic Interaction Network (AIN) analysis, which uniquely identifies an area, or epitope, on the target site that is fundamental to its structure and function. This ideal epitope, or hierotope, becomes the target against which the company designs a novel therapeutic to effectively and durably combat the disease. The company`s lead product candidate, VIS410, is a broad spectrum human monoclonal antibody for the treatment ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Visterra Incorporated raised $23.6M on 10/05/2017

Similar Companies

Adcentrx Therapeutics

Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases.

Lower Valley Ambulance

Lower Valley Ambulance is a Cheswick, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Antiva Biosciences

Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego and builds on his anti-viral expertise as co-founder of Triangle Pharmaceuticals and Chimerix. Antiva`s chemistry platform has yielded over two hundred proprietary pro-drug compounds that are designed to enhance the therapeutic index of known, potent antivirals.

CORRECT PHARMACY

CORRECT PHARMACY is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Providence Therapeutics

Providence is a clinical-stage biotechnology company pioneering mRNA therapeutics and vaccines with a focus on infectious diseases and oncology. Initially founded as a cancer vaccines company in 2015, in response to a worldwide need for a COVID-19 vaccine, Providence expanded its focus beyond oncology therapies to develop an mRNA vaccine for COVID-19. Providence works with multiple industry collaborators, universities, nongovernmental agencies and multiple arms of the Government of Canada to discover and develop vaccines and treatments for infectious diseases and cancer. This has resulted in the development of an mRNA vaccine platform that includes a proprietary design algorithm and proprietary, scalable manufacturing processes.